The present invention is directed to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.
Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7a
, R
7b
and n are as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods for treating an aspartic protease mediated disorder using the same.
The present invention is directed to aspartic protease inhibitors represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.
The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I).
Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.
BISACODYL AND ITS ANALOGUES AS DRUGS FOR USE IN THE TREATMENT OF CANCER
申请人:Feve Marie
公开号:US20140186872A1
公开(公告)日:2014-07-03
The present invention provides compounds having the formula A: (A) or pharmaceutically acceptable salt thereof, wherein W, R1, R2 and R5 are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as cytotoxic agents towards proliferating and/or quiescent cancer stem cells, and thus are useful, for example, for the treatment of cancer.
Disclosed is a process for the preparation of tetrahydropyran-di-amine represented by Structural Formula (I): wherein R
1
is H or alkyl and E is H or an amine protecting group.